bernstein socgen reiterates outperform rating for gsk stock

Published 04/06/2025, 12:44
bernstein socgen reiterates outperform rating for gsk stock

On Wednesday, Bernstein SocGen Group analysts reaffirmed their Outperform rating on GlaxoSmithKline stock, maintaining a price target of INR22.90. The analysts expressed optimism about the company’s future sales, projecting them to exceed both guidance and Bloomberg consensus forecasts by double-digit percentages by 2031, driven by the HIV and pharmaceutical pipelines.

The analysts highlighted two significant events in 2026 that they believe could positively impact GlaxoSmithKline’s price-to-earnings ratio. These include the relaunch of the blood cancer treatment Blenrep in the second half of 2025 and the phase 3 data readouts in 2026 for camlipixant, targeting recurrent chronic cough, and bepirovirsen for hepatitis B.

In their comments, the analysts noted that the current share price underestimates the company’s value, as it reflects a mid-single-digit patent cliff price-to-earnings ratio for GlaxoSmithKline’s pharmaceutical business. They do not foresee the expiration of HIV patents between 2028 and 2030 leading to a significant patent cliff.

The analysts’ positive outlook is based on their belief that these upcoming catalysts and the company’s strong pipeline will lead to upgrades in GlaxoSmithKline’s stock rating. They emphasized that the stock remains undervalued given these potential developments.

GlaxoSmithKline, listed on both the London Stock Exchange (LON:LSEG) (GSK:LN) and the New York Stock Exchange (NYSE:GSK), continues to attract attention from investors and analysts due to its strategic focus on its pharmaceutical and HIV segments.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.